CAJ | 학술논문

目的：观察布地奈德与泼尼松在阻抑和治疗慢性阻塞性肺疾病（ COPD）继发诱导肺间质纤维化患者中的地位和作用，并对两药的安全性进行对比分析。方法：将COPD继发肺间质纤维化患者随机分为布地奈德组（A组）34例，泼尼松组36例（B组），A组给予布地奈德2mg／次（1次／8h）雾化吸入，B组给予泼尼松龙静脉滴注，40mg／次（1次／q12h），分别对比治疗3、5、10d时患者FEV1／预汁值、Pao2、PaCO2情况，并对治疗期间的临床症状评分及不良反应进行对比。结果：治疗后两组FEV1／预计值和动脉血气 PaO2均较入院时升高， PaCO2较入院时降低，其中治疗5d、10d 时 A 组FEV1／预计值／Pa02较B组明显升高，差异有统计学意义（P＜0．05）。经治疗，两组的临床症状评分均明显下降，其中，治疗10d时A组较B组的得分明显降低，差异有统计学意义（ P＜0．05）。两组患者总不良事件发生率没有显著性差异（ P＞0．05）。结论：布地奈德和泼尼松均能改善COPD继发肺间质纤维化患者的肺功能状况，但布地奈德在提高FEV1／预汁值、PaO2、临床症状评分及减少应激反应的中具有长远作用。
목적：관찰포지내덕여발니송재조억화치료만성조새성폐질병（ COPD）계발유도폐간질섬유화환자중적지위화작용，병대량약적안전성진행대비분석。방법：장COPD계발폐간질섬유화환자수궤분위포지내덕조（A조）34례，발니송조36례（B조），A조급여포지내덕2mg／차（1차／8h）무화흡입，B조급여발니송룡정맥적주，40mg／차（1차／q12h），분별대비치료3、5、10d시환자FEV1／예즙치、Pao2、PaCO2정황，병대치료기간적림상증상평분급불량반응진행대비。결과：치료후량조FEV1／예계치화동맥혈기 PaO2균교입원시승고， PaCO2교입원시강저，기중치료5d、10d 시 A 조FEV1／예계치／Pa02교B조명현승고，차이유통계학의의（P＜0．05）。경치료，량조적림상증상평분균명현하강，기중，치료10d시A조교B조적득분명현강저，차이유통계학의의（ P＜0．05）。량조환자총불량사건발생솔몰유현저성차이（ P＞0．05）。결론：포지내덕화발니송균능개선COPD계발폐간질섬유화환자적폐공능상황，단포지내덕재제고FEV1／예즙치、PaO2、림상증상평분급감소응격반응적중구유장원작용。
Objective:To observe lung function of patients with chronic obstructive pulmonary disease ( COPD) secondary repressor and induced pulmonary fibrosis ,compare the safety of the two drugs .Method:The patients with COPD secondary to pulmonary interstitial fibrosis were randomly divided into the budes -onide group (Group A, 34 cases) and prednisone group (Group B,36 patients).Group A were given budes-onide 2mg for onec (1/8h) inhalation, group B were given prednisolone intravenously , 40mg for once (1 /q12h), compared the FEV1/pre-juice value, PaO2, PaCO2 situation after treatment of 3,5, l0 days ,clini-cal symptom scores and adverse reactions were compared either .Result:After treatment, FEV1 /pre-juice value and arterial blood gas PaO 2 , PaCO2 lower than the time of admission , at 5 days, 10 days, group A of FEV1 /pre-juice value,PaO2 were significantly higher than that in group B , the difference there was statisti-cally significant (P<0.05).After treatment, both groups were significantly decreased the clinical symptom scores, at 10 days,the scores of group A was lower than group B , the difference was statistically significant (P<0.05).There was no significant difference between the two groups of patients overall incidence of ad-verse events (P>0.05).Conclusion: Budesonide and prednisone can improve lung function among COPD patients with interstitial fibrosis secondary lung , but budesonide has a long-term effects in improving FEV1 /pre-juice value, PaO2, clinical symptom scores and reduce the stress response .